6-ECDCA (BioDeep_00000010806)

   

Bile acids


代谢物信息卡片


6alpha-Ethyl-chenodeoxycholic acid

化学式: C26H44O4 (420.3239424)
中文名称: 奥贝胆酸
谱图信息: 最多检出来源 Homo sapiens(bile_acids) 33.33%

分子结构信息

SMILES: CCC1C(O)C2C3CCC(C(C)CCC(=O)O)C3(C)CCC2C2(C)CCC(O)CC12
InChI: InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)

描述信息

A - Alimentary tract and metabolism > A05 - Bile and liver therapy > A05A - Bile therapy > A05AA - Bile acids and derivatives
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts
D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
Same as: D09360

同义名列表

5 个代谢物同义名

6alpha-Ethyl-chenodeoxycholic acid; 6-Ethylchenodeoxycholic acid; Obeticholic acid; 6-Ethyl-CDCA; 6-ECDCA



数据库引用编号

14 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Yifan Wang, He Yi, Weixia Sun, Hekai Yu, Wenxuan Tao, Xiaojin Yu, Dianrong Jia, Yingzhao Liu, Stephen J Pandol, Ling Li. Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials. Drugs. 2024 Apr; 84(4):425-439. doi: 10.1007/s40265-024-02015-6. [PMID: 38478331]
  • Juan Li, Zhengcai Ma, Zhipeng Yang, Maochun Yang, Changsheng Li, Mengmeng Li, Xiaoduo Li, Xiantao Chen, Hang Ma, Wanqun Chen, Xiaoli Ye, Xuegang Li. Integrating transcriptomics and network pharmacology to reveal the mechanisms of total Rhizoma Coptidis alkaloids against nonalcoholic steatohepatitis. Journal of ethnopharmacology. 2024 Mar; 322(?):117600. doi: 10.1016/j.jep.2023.117600. [PMID: 38103844]
  • Reza Rahmani, Neda Eivazi, Solaleh Emamgholipour, Mahdi Aminian, Ali Jalilian, Maliheh Paknejad. The obeticholic acid can positively regulate the cancerous behavior of MCF7 breast cancer cell line. Molecular biology reports. 2024 Feb; 51(1):250. doi: 10.1007/s11033-023-09106-9. [PMID: 38302816]
  • Huanfen Lu, Zhenglan Ban, Kai Xiao, Madi Sun, Yongbo Liu, Fangman Chen, Tongfei Shi, Li Chen, Dan Shao, Ming Zhang, Wei Li. Hepatic-Accumulated Obeticholic Acid and Atorvastatin Self-Assembled Nanocrystals Potentiate Ameliorative Effects in Treatment of Metabolic-Associated Fatty Liver Disease. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024 Jan; ?(?):e2308866. doi: 10.1002/advs.202308866. [PMID: 38196299]
  • Anila Kutty Narayanan, Sudhindran Surendran, Dinesh Balakrishnan, Unnikrishnan Gopalakrishnan, Shweta Malick, Arun Valsan, Cyriac Abby Philips, Christopher John Edward Watson. A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor. Current reviews in clinical and experimental pharmacology. 2024; 19(3):225-233. doi: 10.2174/0127724328239536230919070001. [PMID: 38708917]
  • Luciano Adorini, Kristoffer Rigbolt, Michael Feigh, Jonathan Roth, Mary Erickson. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. PloS one. 2024; 19(4):e0300809. doi: 10.1371/journal.pone.0300809. [PMID: 38662778]
  • Arezou Azizsoltani, Behzad Hatami, Mohammad Reza Zali, Vahideh Mahdavi, Kaveh Baghaei, Effat Alizadeh. Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting of the FXR signaling pathway and ECM remodeling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Dec; 168(?):115777. doi: 10.1016/j.biopha.2023.115777. [PMID: 37913732]
  • Hyejung Jang, Nayoung Han, Christine E Staatz, Jae-Hwan Kwak, In-Hwan Baek. Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis. Clinics and research in hepatology and gastroenterology. 2023 Oct; 47(10):102227. doi: 10.1016/j.clinre.2023.102227. [PMID: 37884091]
  • Ming Liang, Huailiang Yang, Lanyong Xu, Longqiao Cao. Obeticholic acid treatment of mice to promote fertilization and reproduction. Zygote (Cambridge, England). 2023 Sep; ?(?):1-10. doi: 10.1017/s0967199423000400. [PMID: 37655605]
  • Jaclynn A Meshanni, Jordan M Lee, Kinal N Vayas, Rachel Sun, Chenghui Jiang, Grace L Guo, Andrew J Gow, Jeffrey D Laskin, Debra L Laskin. Suppression of lung oxidative stress, inflammation and fibrosis following nitrogen mustard exposure by the selective farnesoid X receptor agonist obeticholic acid. The Journal of pharmacology and experimental therapeutics. 2023 May; ?(?):. doi: 10.1124/jpet.123.001557. [PMID: 37188530]
  • Jing Zhao, Guochao Song, Fengyi Weng, Yue Li, Bin Zou, Jingyi Jin, Dongming Yan, Xin Sun, Chenghai Liu, Fu-Rong Qiu. The choleretic role of TUDCA exacerbates ANIT-induced cholestatic liver injury through the FXR/BSEP pathway. Journal of applied toxicology : JAT. 2023 Feb; ?(?):. doi: 10.1002/jat.4446. [PMID: 36787806]
  • Aoxiang Zhuge, Shengjie Li, Yin Yuan, Shengyi Han, Jiafeng Xia, Qiangqiang Wang, Shuting Wang, Pengcheng Lou, Bo Li, Lanjuan Li. Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice. Redox biology. 2023 02; 59(?):102582. doi: 10.1016/j.redox.2022.102582. [PMID: 36584600]
  • Cristina Zivko, Finja Witt, Andreas Koeberle, Gregor Fuhrmann, Paola Luciani. Formulating elafibranor and obeticholic acid with phospholipids decreases drug-induced association of SPARC to extracellular vesicles from LX-2 human hepatic stellate cells. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2023 Jan; 182(?):32-40. doi: 10.1016/j.ejpb.2022.11.025. [PMID: 36470521]
  • Rumei Li, Milaine V Hovingh, Martijn Koehorst, Pim de Blaauw, Henkjan J Verkade, Jan Freark de Boer, Folkert Kuipers. Short-term obeticholic acid treatment does not impact cholangiopathy in Cyp2c70-deficient mice with a human-like bile acid composition. Biochimica et biophysica acta. Molecular and cell biology of lipids. 2022 08; 1867(8):159163. doi: 10.1016/j.bbalip.2022.159163. [PMID: 35470044]
  • Can Hu, Ya Li, Yujie Liu, Yong Lai, Li Ding. A Sensitive HPLC-MS/MS Method for Determination of Obeticholic Acid in Human Plasma: Application to a Pharmacokinetic Study in Healthy Volunteers. Journal of chromatographic science. 2022 Jul; 60(6):545-550. doi: 10.1093/chromsci/bmab098. [PMID: 34313291]
  • Zongtao Zhou, Qiang Ren, Shixuan Jiao, Zongyu Cai, Xinqian Geng, Liming Deng, Bin Wang, Lijun Hu, Luyong Zhang, Ying Yang, Zheng Li. Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents. European journal of medicinal chemistry. 2022 Feb; 229(?):114061. doi: 10.1016/j.ejmech.2021.114061. [PMID: 34954593]
  • Szu-Yu Liu, Chia-Chang Huang, Ying-Ying Yang, Shiang-Fen Huang, Tzung-Yan Lee, Tzu-Hao Li, Ming-Chih Hou, Han-Chieh Lin. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice. PloS one. 2022; 17(12):e0276717. doi: 10.1371/journal.pone.0276717. [PMID: 36490253]
  • Yuanying Fang, Lamees Hegazy, Brian N Finck, Bahaa Elgendy. Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor. Journal of medicinal chemistry. 2021 12; 64(24):17545-17571. doi: 10.1021/acs.jmedchem.1c01017. [PMID: 34889100]
  • Liping Wang, Qing Luo, Sijing Zeng, Yanmei Lou, Xiaoyan Li, Ming Hu, Linlin Lu, Zhongqiu Liu. Disordered farnesoid X receptor signaling is associated with liver carcinogenesis in Abcb11-deficient mice. The Journal of pathology. 2021 12; 255(4):412-424. doi: 10.1002/path.5780. [PMID: 34410012]
  • Suling Huang, Yanwei Wu, Zhuohui Zhao, Bing Wu, Kai Sun, Haoyu Wang, Li Qin, Fang Bai, Ying Leng, Wei Tang. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage. Metabolism: clinical and experimental. 2021 07; 120(?):154797. doi: 10.1016/j.metabol.2021.154797. [PMID: 33984334]
  • Xiaojiao Li, Hong Zhang, Cuiyun Li, Wenbo Zheng, Meng Wang, Min Wu, Deming Yang, Yue Hu, Dandan Huo, Zhongnan Xu, Yanhua Ding, Li Liu. Comparison of the Pharmacokinetics of Generic Versus Branded Obeticholic Acid in a Chinese Population: Effects of Food and Sex. Clinical pharmacology in drug development. 2021 07; 10(7):797-806. doi: 10.1002/cpdd.905. [PMID: 33463088]
  • Fei Xiong, Zhongdaixi Zheng, Lingyu Xiao, Chuhong Su, Junbin Chen, Xiangfu Gu, Jiaqi Tang, Yue Zhao, Huiyu Luo, Longying Zha. Soyasaponin A2 Alleviates Steatohepatitis Possibly through Regulating Bile Acids and Gut Microbiota in the Methionine and Choline-Deficient (MCD) Diet-induced Nonalcoholic Steatohepatitis (NASH) Mice. Molecular nutrition & food research. 2021 07; 65(14):e2100067. doi: 10.1002/mnfr.202100067. [PMID: 34047448]
  • Junxiao Li, Chuhe Liu, Zhenyu Zhou, Baokai Dou, Jinwen Huang, Leilei Huang, Peiyong Zheng, Shengjie Fan, Cheng Huang. Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice. Phytotherapy research : PTR. 2021 Jun; 35(6):3351-3364. doi: 10.1002/ptr.7055. [PMID: 33784797]
  • Lori W E van der Schoor, Henkjan J Verkade, Anna Bertolini, Sanne de Wit, Elvira Mennillo, Eva Rettenmeier, André A Weber, Rick Havinga, Petra Valášková, Jana Jašprová, Dicky Struik, Vincent W Bloks, Shujuan Chen, Andrea B Schreuder, Libor Vítek, Robert H Tukey, Johan W Jonker. Potential of therapeutic bile acids in the treatment of neonatal Hyperbilirubinemia. Scientific reports. 2021 05; 11(1):11107. doi: 10.1038/s41598-021-90687-5. [PMID: 34045606]
  • Lulu Sun, Jie Cai, Frank J Gonzalez. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nature reviews. Gastroenterology & hepatology. 2021 05; 18(5):335-347. doi: 10.1038/s41575-020-00404-2. [PMID: 33568795]
  • Venkat Rao Valluri, Naresh Kumar Katari, Chirag Khatri, Siva Sankara Rao Yadlapalli, Krishnan Anand, Rambabu Gundla, Srinivasa Rao Polagani. A novel LC-MS/MS method for simultaneous estimation of obeticholic acid, glyco-obeticholic acid, tauro-obeticholic acid in human plasma and its application to a pharmacokinetic study. Journal of separation science. 2021 Apr; 44(7):1307-1323. doi: 10.1002/jssc.202001050. [PMID: 33395497]
  • Jingwen Zhou, Yidi Chen, Jun Yu, Tianci Li, Ziyu Lu, Yan Chen, Xiaolong Zhang, Fang Ye. The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials. Medicine. 2021 Mar; 100(12):e24884. doi: 10.1097/md.0000000000024884. [PMID: 33761646]
  • Li Wu, Yuqiu Han, Zhipeng Zheng, Shuai Zhu, Jun Chen, Yuanyuan Yao, Siqing Yue, Andreas Teufel, Honglei Weng, Lanjuan Li, Baohong Wang. Obeticholic Acid Inhibits Anxiety via Alleviating Gut Microbiota-Mediated Microglia Accumulation in the Brain of High-Fat High-Sugar Diet Mice. Nutrients. 2021 Mar; 13(3):. doi: 10.3390/nu13030940. [PMID: 33803974]
  • Maaike Blankestijn, Ivo P van de Peppel, Ales Dvorak, Nikola Capkova, Libor Vitek, Johan W Jonker, Henkjan J Verkade. Induction of fecal cholesterol excretion is not effective for the treatment of hyperbilirubinemia in Gunn rats. Pediatric research. 2021 02; 89(3):510-517. doi: 10.1038/s41390-020-0926-2. [PMID: 32357361]
  • Suzanna L Attia, Samir Softic, Marialena Mouzaki. Evolving Role for Pharmacotherapy in NAFLD/NASH. Clinical and translational science. 2021 01; 14(1):11-19. doi: 10.1111/cts.12839. [PMID: 32583961]
  • André A Weber, Elvira Mennillo, Xiaojing Yang, Lori W E van der Schoor, Johan W Jonker, Shujuan Chen, Robert H Tukey. Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation. Drug metabolism and disposition: the biological fate of chemicals. 2021 01; 49(1):12-19. doi: 10.1124/dmd.120.000240. [PMID: 33154041]
  • Yuan Gao, Li Li, Bei Li, Yutao Zhan. Response Rate and Impact on Lipid Profiles of Obeticholic Acid Treatment for Patients with Primary Biliary Cholangitis: A Meta-Analysis. Canadian journal of gastroenterology & hepatology. 2021; 2021(?):8829510. doi: 10.1155/2021/8829510. [PMID: 33511089]
  • Lin Guan, Peng Miao. Systematic review and meta-analysis of randomized controlled trials on the effects of obeticholic acid on the blood lipid profile: Insights into liver disorders and liver cancer. European journal of pharmacology. 2020 Dec; 889(?):173616. doi: 10.1016/j.ejphar.2020.173616. [PMID: 33035521]
  • Junyou Li, Mengqi Liu, Yazhou Li, Dan-Dan Sun, Zhihao Shu, Qian Tan, Shimeng Guo, Rongrong Xie, Lixin Gao, Hongbo Ru, Yi Zang, Hong Liu, Jia Li, Yu Zhou. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis. Journal of medicinal chemistry. 2020 11; 63(21):12748-12772. doi: 10.1021/acs.jmedchem.0c01065. [PMID: 32991173]
  • Michael Camilleri, Priya Vijayvargiya. The Role of Bile Acids in Chronic Diarrhea. The American journal of gastroenterology. 2020 10; 115(10):1596-1603. doi: 10.14309/ajg.0000000000000696. [PMID: 32558690]
  • Ying Wang, Yao Zhu, Junxing Niu, Qiangqiang Deng, Shimeng Guo, Haowen Jiang, Zhaoliang Peng, Yaru Xue, Huige Peng, Lijiang Xuan, Guoyu Pan. A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters. Toxicology and applied pharmacology. 2020 10; 404(?):115169. doi: 10.1016/j.taap.2020.115169. [PMID: 32738331]
  • Ruibing Feng, Li-Juan Ma, Meng Wang, Conghui Liu, Rujie Yang, Huanxing Su, Yan Yang, Jian-Bo Wan. Oxidation of fish oil exacerbates alcoholic liver disease by enhancing intestinal dysbiosis in mice. Communications biology. 2020 09; 3(1):481. doi: 10.1038/s42003-020-01213-8. [PMID: 32879433]
  • Xuan Li, Min Liao, Qiong Pan, Qiaoling Xie, Hong Yang, Ying Peng, Qiao Li, Jiaquan Qu, Jin Chai. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review. European journal of gastroenterology & hepatology. 2020 09; 32(9):1116-1122. doi: 10.1097/meg.0000000000001785. [PMID: 32649329]
  • Yu-Lien Tsai, Chih-Wei Liu, Chien-Fu Hsu, Chia-Chang Huang, Ming-Wei Lin, Shiang-Fen Huang, Tzu-Hao Li, Kuei-Chuan Lee, Yun-Cheng Hsieh, Ying-Ying Yang, Tzung-Yan Lee, Hsuan-Miao Liu, Yi-Hsiang Huang, Ming-Chih Hou, Han-Chieh Lin. Obeticholic acid ameliorates hepatorenal syndrome in ascitic cirrhotic rats by down-regulating the renal 8-iso-PGF2α-activated COX-TXA2 pathway. Clinical science (London, England : 1979). 2020 08; 134(15):2055-2073. doi: 10.1042/cs20200452. [PMID: 32725149]
  • Vanessa Pataia, Saraid McIlvride, Georgia Papacleovoulou, Caroline Ovadia, Julie A K McDonald, Annika Wahlström, Eugène Jansen, Luciano Adorini, David Shapiro, Julian R Marchesi, Hanns-Ulrich Marschall, Catherine Williamson. Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia. American journal of physiology. Gastrointestinal and liver physiology. 2020 08; 319(2):G197-G211. doi: 10.1152/ajpgi.00126.2020. [PMID: 32597707]
  • Kris V Kowdley, Raj Vuppalanchi, Cynthia Levy, Annarosa Floreani, Pietro Andreone, Nicholas F LaRusso, Roshan Shrestha, James Trotter, David Goldberg, Simon Rushbrook, Gideon M Hirschfield, Thomas Schiano, Yuying Jin, Richard Pencek, Leigh MacConell, David Shapiro, Christopher L Bowlus. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis. Journal of hepatology. 2020 07; 73(1):94-101. doi: 10.1016/j.jhep.2020.02.033. [PMID: 32165251]
  • Yu Yang, Yu Zhao, Wenzhen Li, Yuyao Wu, Xin Wang, Yijie Wang, Tingmei Liu, Tinghong Ye, Yongmei Xie, Zhiqiang Cheng, Jun He, Peng Bai, Yiwen Zhang, Liang Ouyang. Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment. European journal of medicinal chemistry. 2020 Jul; 197(?):112311. doi: 10.1016/j.ejmech.2020.112311. [PMID: 32339855]
  • Cheng Zhang, Yu Gan, Jin-Wei Lv, Ming-Qiang Qin, Wei-Rong Hu, Zhi-Bing Liu, Li Ma, Bing-Dong Song, Jian Li, Wei-Ying Jiang, Jian-Qing Wang, Hua Wang, De-Xiang Xu. The protective effect of obeticholic acid on lipopolysaccharide-induced disorder of maternal bile acid metabolism in pregnant mice. International immunopharmacology. 2020 Jun; 83(?):106442. doi: 10.1016/j.intimp.2020.106442. [PMID: 32248018]
  • F Anthony Romero, Christopher T Jones, Yingzi Xu, Martijn Fenaux, Randall L Halcomb. The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. Journal of medicinal chemistry. 2020 05; 63(10):5031-5073. doi: 10.1021/acs.jmedchem.9b01701. [PMID: 31930920]
  • Roger W Chapman, Kate D Lynch. Obeticholic acid-a new therapy in PBC and NASH. British medical bulletin. 2020 05; 133(1):95-104. doi: 10.1093/bmb/ldaa006. [PMID: 32282030]
  • Zhibo Gai, Evelin Krajnc, Sophia L Samodelov, Michele Visentin, Gerd A Kullak-Ublick. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress. Molecular pharmacology. 2020 05; 97(5):314-323. doi: 10.1124/mol.119.118646. [PMID: 32098797]
  • Donatella Chianelli, Paul V Rucker, Jason Roland, David C Tully, John Nelson, Xiaodong Liu, Badry Bursulaya, Eloy D Hernandez, Jane Wu, Mahavir Prashad, Thierry Schlama, Yugang Liu, Alan Chu, James Schmeits, David J Huang, Robert Hill, Dingjiu Bao, Jocelyn Zoll, Young Kim, Todd Groessl, Peter McNamara, Bo Liu, Wendy Richmond, Ignacio Sancho-Martinez, Andrew Phimister, H Martin Seidel, Michael K Badman, Sean B Joseph, Bryan Laffitte, Valentina Molteni. Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. Journal of medicinal chemistry. 2020 04; 63(8):3868-3880. doi: 10.1021/acs.jmedchem.9b01621. [PMID: 31940200]
  • Jiyu Zhou, Shuang Cui, Qingxian He, Yitong Guo, Xiaojie Pan, Pengfei Zhang, Ningning Huang, Chaoliang Ge, Guangji Wang, Frank J Gonzalez, Hong Wang, Haiping Hao. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis. Nature communications. 2020 01; 11(1):240. doi: 10.1038/s41467-019-14138-6. [PMID: 31932588]
  • Mohammad Shadab Siddiqui, Mark L Van Natta, Margery A Connelly, Raj Vuppalanchi, Brent A Neuschwander-Tetri, James Tonascia, Cynthia Guy, Rohit Loomba, Srinivasan Dasarathy, Julia Wattacheril, Naga Chalasani, Arun J Sanyal. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. Journal of hepatology. 2020 01; 72(1):25-33. doi: 10.1016/j.jhep.2019.10.006. [PMID: 31634532]
  • Andrea Ferrigno, Giuseppina Palladini, Laura Giuseppina Di Pasqua, Clarissa Berardo, Plinio Richelmi, Massimiliano Cadamuro, Luca Fabris, Stefano Perlini, Luciano Adorini, Mariapia Vairetti. Obeticholic acid reduces biliary and hepatic matrix metalloproteinases activity in rat hepatic ischemia/reperfusion injury. PloS one. 2020; 15(9):e0238543. doi: 10.1371/journal.pone.0238543. [PMID: 32911524]
  • Ali Saeed, Jing Yang, Janette Heegsma, Albert K Groen, Saskia W C van Mil, Coen C Paulusma, Lu Zhou, Bangmao Wang, Klaas Nico Faber. Farnesoid X receptor and bile acids regulate vitamin A storage. Scientific reports. 2019 12; 9(1):19493. doi: 10.1038/s41598-019-55988-w. [PMID: 31862954]
  • Qingfa Chen, Hongling Ma, Xuewen Guo, Jia Liu, Ting Gui, Zhibo Gai. Farnesoid X Receptor (FXR) Aggravates Amyloid-β-Triggered Apoptosis by Modulating the cAMP-Response Element-Binding Protein (CREB)/Brain-Derived Neurotrophic Factor (BDNF) Pathway In Vitro. Medical science monitor : international medical journal of experimental and clinical research. 2019 Dec; 25(?):9335-9345. doi: 10.12659/msm.920065. [PMID: 31812977]
  • Li Ren, Qing Song, Yunhuan Liu, Lihua Zhang, Zhiming Hao, Wenke Feng. Probiotic Lactobacillus rhamnosus GG prevents progesterone metabolite epiallaopregnanolone sulfate-induced hepatic bile acid accumulation and liver injury. Biochemical and biophysical research communications. 2019 11; 520(1):67-72. doi: 10.1016/j.bbrc.2019.09.103. [PMID: 31575408]
  • Vasiliki Venetsanaki, Zacharoula Karabouta, Stergios A Polyzos. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis. European journal of pharmacology. 2019 Nov; 863(?):172661. doi: 10.1016/j.ejphar.2019.172661. [PMID: 31536725]
  • Paul J Pockros, Michael Fuchs, Bradley Freilich, Eugene Schiff, Anita Kohli, Eric J Lawitz, Paul A Hellstern, Janet Owens-Grillo, Courtney Van Biene, Reshma Shringarpure, Leigh MacConell, David Shapiro, David E Cohen. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver international : official journal of the International Association for the Study of the Liver. 2019 11; 39(11):2082-2093. doi: 10.1111/liv.14209. [PMID: 31402538]
  • Samer Al-Dury, Annika Wahlström, Katrin Panzitt, Anders Thorell, Marcus Ståhlman, Michael Trauner, Peter Fickert, Fredrik Bäckhed, Lars Fändriks, Martin Wagner, Hanns-Ulrich Marschall. Obeticholic acid may increase the risk of gallstone formation in susceptible patients. Journal of hepatology. 2019 11; 71(5):986-991. doi: 10.1016/j.jhep.2019.06.011. [PMID: 31254596]
  • Adriana Carino, Michele Biagioli, Silvia Marchianò, Chiara Fiorucci, Angela Zampella, Maria Chiara Monti, Paolo Scarpelli, Patrizia Ricci, Eleonora Distrutti, Stefano Fiorucci. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. Biochimica et biophysica acta. Molecular and cell biology of lipids. 2019 10; 1864(10):1422-1437. doi: 10.1016/j.bbalip.2019.07.006. [PMID: 31325638]
  • Hongkui Wu, Gang Liu, Yaoli He, Jing Da, Bingqing Xie. Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice. European journal of pharmacology. 2019 Sep; 858(?):172393. doi: 10.1016/j.ejphar.2019.05.022. [PMID: 31085240]
  • Dandan Zhou, Linghua Kong, Yiguo Jiang, Cheng Wang, Yao Ni, Yedong Wang, Hongjian Zhang, Jianqing Ruan. UGT-dependent regioselective glucuronidation of ursodeoxycholic acid and obeticholic acid and selective transport of the consequent acyl glucuronides by OATP1B1 and 1B3. Chemico-biological interactions. 2019 Sep; 310(?):108745. doi: 10.1016/j.cbi.2019.108745. [PMID: 31299240]
  • Saraid McIlvride, Vanya Nikolova, Hei Man Fan, Julie A K McDonald, Annika Wahlström, Elena Bellafante, Eugene Jansen, Luciano Adorini, David Shapiro, Peter Jones, Julian R Marchesi, Hanns-Ulrich Marschall, Catherine Williamson. Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes. American journal of physiology. Endocrinology and metabolism. 2019 08; 317(2):E399-E410. doi: 10.1152/ajpendo.00407.2018. [PMID: 31237448]
  • Md Abdul Hye Khan, Jurema Schmidt, Anna Stavniichuk, John D Imig, Daniel Merk. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. Biochemical pharmacology. 2019 08; 166(?):212-221. doi: 10.1016/j.bcp.2019.05.023. [PMID: 31129048]
  • Xiang-Yu Li, Sheng-Hong Zhu, Fang Yang, Guo-Xin Hu, Ling-Jing Yuan. An ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of obeticholic acid in rat plasma and its application in preclinical pharmacokinetic studies. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2019 Jul; 1121(?):82-88. doi: 10.1016/j.jchromb.2019.05.011. [PMID: 31129439]
  • Jonathan D Roth, Sanne S Veidal, Louise K D Fensholdt, Kristoffer T G Rigbolt, Romeo Papazyan, Jens Christian Nielsen, Michael Feigh, Niels Vrang, Mark Young, Jacob Jelsing, Luciano Adorini, Henrik H Hansen. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH. Scientific reports. 2019 06; 9(1):9046. doi: 10.1038/s41598-019-45178-z. [PMID: 31227742]
  • Vignan Manne, Kris V Kowdley. Obeticholic acid in primary biliary cholangitis: where we stand. Current opinion in gastroenterology. 2019 05; 35(3):191-196. doi: 10.1097/mog.0000000000000525. [PMID: 30844895]
  • Bin Dong, Amar B Singh, Grace L Guo, Mark Young, Jingwen Liu. Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR. International journal of molecular medicine. 2019 May; 43(5):1927-1938. doi: 10.3892/ijmm.2019.4136. [PMID: 30896855]
  • Naga Chalasani, Manal F Abdelmalek, Rohit Loomba, Kris V Kowdley, Arthur J McCullough, Srinivasan Dasarathy, Brent A Neuschwander-Tetri, Norah Terrault, Beatrice Ferguson, Reshma Shringarpure, David Shapiro, Arun J Sanyal. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver international : official journal of the International Association for the Study of the Liver. 2019 05; 39(5):924-932. doi: 10.1111/liv.13974. [PMID: 30253043]
  • Meng Hua Li, Wei Chen, Li Li Wang, Jia Lin Sun, Lei Zhou, Yu Cong Shi, Chu Han Wang, Bo Hua Zhong, Wei Guo Shi, Zhong Wu Guo. RLA8-A New and Highly Effective Quadruple PPAR-α/γ/δ and GPR40 Agonist to Reverse Nonalcoholic Steatohepatitis and Fibrosis. The Journal of pharmacology and experimental therapeutics. 2019 04; 369(1):67-77. doi: 10.1124/jpet.118.255216. [PMID: 30745416]
  • Stefano Fiorucci, Cristina Di Giorgio, Eleonora Distrutti. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders. Handbook of experimental pharmacology. 2019; 256(?):283-295. doi: 10.1007/164_2019_227. [PMID: 31201552]
  • Jun Fei, Lin Fu, Biao Hu, Yuan-Hua Chen, Hui Zhao, De-Xiang Xu, Jia-Bin Li. Obeticholic acid alleviate lipopolysaccharide-induced acute lung injury via its anti-inflammatory effects in mice. International immunopharmacology. 2019 Jan; 66(?):177-184. doi: 10.1016/j.intimp.2018.11.005. [PMID: 30468885]
  • Wei Chen, Xing-Xing Gao, Li Ma, Zhi-Bing Liu, Li Li, Hua Wang, Lan Gao, De-Xiang Xu, Yuan-Hua Chen. Obeticholic Acid Protects against Gestational Cholestasis-Induced Fetal Intrauterine Growth Restriction in Mice. Oxidative medicine and cellular longevity. 2019; 2019(?):7419249. doi: 10.1155/2019/7419249. [PMID: 31827696]
  • Elliot S Friedman, Yun Li, Ting-Chin David Shen, Jack Jiang, Lillian Chau, Luciano Adorini, Farah Babakhani, Jeffrey Edwards, David Shapiro, Chunyu Zhao, Rotonya M Carr, Kyle Bittinger, Hongzhe Li, Gary D Wu. FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid. Gastroenterology. 2018 12; 155(6):1741-1752.e5. doi: 10.1053/j.gastro.2018.08.022. [PMID: 30144429]
  • Jin-Bo Zhu, Shen Xu, Jun Li, Jin Song, Biao Luo, Ya-Ping Song, Zhi-Hui Zhang, Yuan-Hua Chen, Dong-Dong Xie, De-Xin Yu, De-Xiang Xu. Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury. European journal of pharmacology. 2018 Nov; 838(?):60-68. doi: 10.1016/j.ejphar.2018.09.009. [PMID: 30196109]
  • Suchun Li, Miaojuan Qiu, Yonglun Kong, Xiaoduo Zhao, Hyo-Jung Choi, Maria Reich, Brady H Bunkelman, Qiaojuan Liu, Shan Hu, Mengke Han, Haixia Xie, Avi Z Rosenberg, Verena Keitel, Tae-Hwan Kwon, Moshe Levi, Chunling Li, Weidong Wang. Bile Acid G Protein-Coupled Membrane Receptor TGR5 Modulates Aquaporin 2-Mediated Water Homeostasis. Journal of the American Society of Nephrology : JASN. 2018 11; 29(11):2658-2670. doi: 10.1681/asn.2018030271. [PMID: 30305310]
  • Hong Wang, Qingxian He, Guangji Wang, Xiaowei Xu, Haiping Hao. FXR modulators for enterohepatic and metabolic diseases. Expert opinion on therapeutic patents. 2018 11; 28(11):765-782. doi: 10.1080/13543776.2018.1527906. [PMID: 30259754]
  • Amar Bahadur Singh, Bin Dong, Fredric B Kraemer, Yanyong Xu, Yanqiao Zhang, Jingwen Liu. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice. Arteriosclerosis, thrombosis, and vascular biology. 2018 10; 38(10):2448-2459. doi: 10.1161/atvbaha.118.311122. [PMID: 30354208]
  • Maddalena Parafati, R Jason Kirby, Sepideh Khorasanizadeh, Fraydoon Rastinejad, Siobhan Malany. A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis. Disease models & mechanisms. 2018 09; 11(9):. doi: 10.1242/dmm.033530. [PMID: 30254132]
  • Gideon M Hirschfield, Jessica K Dyson, Graeme J M Alexander, Michael H Chapman, Jane Collier, Stefan Hübscher, Imran Patanwala, Stephen P Pereira, Collette Thain, Douglas Thorburn, Dina Tiniakos, Martine Walmsley, George Webster, David E J Jones. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018 09; 67(9):1568-1594. doi: 10.1136/gutjnl-2017-315259. [PMID: 29593060]
  • Xuan Wang, Shuo Li, Man Chen, Jing Liu, Ruirui Dong, Huamin Wang, Shigong Zhu. Activation of the Nuclear Receptor Fxr Improves Intestinal Cell Tolerance to Ischemia-Reperfusion Injury. Shock (Augusta, Ga.). 2018 09; 50(3):316-323. doi: 10.1097/shk.0000000000001019. [PMID: 29028769]
  • Zhibo Gai, Michele Visentin, Ting Gui, Lin Zhao, Wolfgang E Thasler, Stephanie Häusler, Ivan Hartling, Alessio Cremonesi, Christian Hiller, Gerd A Kullak-Ublick. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation. Molecular pharmacology. 2018 08; 94(2):802-811. doi: 10.1124/mol.117.111047. [PMID: 29743187]
  • Romeo Papazyan, Xueqing Liu, Jingwen Liu, Bin Dong, Emily M Plummer, Ronald D Lewis, Jonathan D Roth, Mark A Young. FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. Journal of lipid research. 2018 06; 59(6):982-993. doi: 10.1194/jlr.m081935. [PMID: 29559521]
  • Adriana Carino, Michele Biagioli, Silvia Marchianò, Paolo Scarpelli, Angela Zampella, Vittorio Limongelli, Stefano Fiorucci. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand. Pharmacological research. 2018 05; 131(?):17-31. doi: 10.1016/j.phrs.2018.02.033. [PMID: 29530598]
  • B Hameed, N A Terrault, R M Gill, R Loomba, N Chalasani, J H Hoofnagle, M L Van Natta. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Alimentary pharmacology & therapeutics. 2018 03; 47(5):645-656. doi: 10.1111/apt.14492. [PMID: 29333665]
  • Stefano Gitto, Valeria Guarneri, Alessandro Sartini, Pietro Andreone. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives. Expert review of gastroenterology & hepatology. 2018 Feb; 12(2):165-171. doi: 10.1080/17474124.2018.1399060. [PMID: 29082798]
  • Kirstine S Tølbøl, Maria Nb Kristiansen, Henrik H Hansen, Sanne S Veidal, Kristoffer Tg Rigbolt, Matthew P Gillum, Jacob Jelsing, Niels Vrang, Michael Feigh. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World journal of gastroenterology. 2018 Jan; 24(2):179-194. doi: 10.3748/wjg.v24.i2.179. [PMID: 29375204]
  • Andrea Ferrigno, Laura Giuseppina Di Pasqua, Clarissa Berardo, Veronica Siciliano, Vittoria Rizzo, Luciano Adorini, Plinio Richelmi, Mariapia Vairetti. The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury. PloS one. 2018; 13(1):e0191430. doi: 10.1371/journal.pone.0191430. [PMID: 29346429]
  • Xiaoxin X Wang, Dong Wang, Yuhuan Luo, Komuraiah Myakala, Evgenia Dobrinskikh, Avi Z Rosenberg, Jonathan Levi, Jeffrey B Kopp, Amanda Field, Ashley Hill, Scott Lucia, Liru Qiu, Tao Jiang, Yingqiong Peng, David Orlicky, Gabriel Garcia, Michal Herman-Edelstein, Vivette D'Agati, Kammi Henriksen, Luciano Adorini, Mark Pruzanski, Cen Xie, Kristopher W Krausz, Frank J Gonzalez, Suman Ranjit, Alexander Dvornikov, Enrico Gratton, Moshe Levi. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. Journal of the American Society of Nephrology : JASN. 2018 01; 29(1):118-137. doi: 10.1681/asn.2017020222. [PMID: 29089371]
  • Annarosa Floreani, Chiara Mangini. Primary biliary cholangitis: Old and novel therapy. European journal of internal medicine. 2018 01; 47(?):1-5. doi: 10.1016/j.ejim.2017.06.020. [PMID: 28669591]
  • Xi Xiong, Yuqian Ren, Yun Cui, Rui Li, Chunxia Wang, Yucai Zhang. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2017 Dec; 96(?):1292-1298. doi: 10.1016/j.biopha.2017.11.083. [PMID: 29174575]
  • Hani Jouihan, Sarah Will, Silvia Guionaud, Michelle L Boland, Stephanie Oldham, Peter Ravn, Anthony Celeste, James L Trevaskis. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice. Molecular metabolism. 2017 11; 6(11):1360-1370. doi: 10.1016/j.molmet.2017.09.001. [PMID: 29107284]
  • Jan Dusek, Alejandro Carazo, Frantisek Trejtnar, Lucie Hyrsova, Ondřej Holas, Tomas Smutny, Stanislav Micuda, Petr Pavek. Steviol, an aglycone of steviol glycoside sweeteners, interacts with the pregnane X (PXR) and aryl hydrocarbon (AHR) receptors in detoxification regulation. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2017 Nov; 109(Pt 1):130-142. doi: 10.1016/j.fct.2017.09.007. [PMID: 28887089]
  • Paolo Comeglio, Annamaria Morelli, Luciano Adorini, Mario Maggi, Linda Vignozzi. Beneficial effects of bile acid receptor agonists in pulmonary disease models. Expert opinion on investigational drugs. 2017 Nov; 26(11):1215-1228. doi: 10.1080/13543784.2017.1385760. [PMID: 28949776]
  • Jeffrey E Edwards, Lise Eliot, Andrew Parkinson, Sharon Karan, Leigh MacConell. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects. Advances in therapy. 2017 09; 34(9):2120-2138. doi: 10.1007/s12325-017-0601-0. [PMID: 28808886]
  • Michael S Middleton, Elhamy R Heba, Catherine A Hooker, Mustafa R Bashir, Kathryn J Fowler, Kumar Sandrasegaran, Elizabeth M Brunt, David E Kleiner, Edward Doo, Mark L Van Natta, Joel E Lavine, Brent A Neuschwander-Tetri, Arun Sanyal, Rohit Loomba, Claude B Sirlin. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. Gastroenterology. 2017 09; 153(3):753-761. doi: 10.1053/j.gastro.2017.06.005. [PMID: 28624576]
  • Daniel Flesch, Sun-Yee Cheung, Jurema Schmidt, Matthias Gabler, Pascal Heitel, Jan Kramer, Astrid Kaiser, Markus Hartmann, Mara Lindner, Kerstin Lüddens-Dämgen, Jan Heering, Christina Lamers, Hartmut Lüddens, Mario Wurglics, Ewgenij Proschak, Manfred Schubert-Zsilavecz, Daniel Merk. Nonacidic Farnesoid X Receptor Modulators. Journal of medicinal chemistry. 2017 08; 60(16):7199-7205. doi: 10.1021/acs.jmedchem.7b00903. [PMID: 28749691]
  • A Roda, R Aldini, C Camborata, S Spinozzi, P Franco, M Cont, A D'Errico, F Vasuri, A Degiovanni, L Maroni, L Adorini. Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis. Clinical and translational science. 2017 Jul; 10(4):292-301. doi: 10.1111/cts.12468. [PMID: 28411380]
  • Vittoria Massafra, Alexandra Milona, Harmjan R Vos, Rúben J J Ramos, Johan Gerrits, Ellen C L Willemsen, José M Ramos Pittol, Noortje Ijssennagger, Martin Houweling, Hubertus C M T Prinsen, Nanda M Verhoeven-Duif, Boudewijn M T Burgering, Saskia W C van Mil. Farnesoid X Receptor Activation Promotes Hepatic Amino Acid Catabolism and Ammonium Clearance in Mice. Gastroenterology. 2017 05; 152(6):1462-1476.e10. doi: 10.1053/j.gastro.2017.01.014. [PMID: 28130067]
  • P B Olthof, F Huisman, F G Schaap, K P van Lienden, R J Bennink, R F van Golen, M Heger, J Verheij, P L Jansen, S W Olde Damink, T M van Gulik. Effect of obeticholic acid on liver regeneration following portal vein embolization in an experimental model. The British journal of surgery. 2017 Apr; 104(5):590-599. doi: 10.1002/bjs.10466. [PMID: 28195307]
  • Paolo Comeglio, Sandra Filippi, Erica Sarchielli, Annamaria Morelli, Ilaria Cellai, Francesca Corcetto, Chiara Corno, Elena Maneschi, Alessandro Pini, Luciano Adorini, Gabriella Barbara Vannelli, Mario Maggi, Linda Vignozzi. Anti-fibrotic effects of chronic treatment with the selective FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis. The Journal of steroid biochemistry and molecular biology. 2017 04; 168(?):26-37. doi: 10.1016/j.jsbmb.2017.01.010. [PMID: 28115235]
  • Bin Dong, Mark Young, Xueqing Liu, Amar Bahadur Singh, Jingwen Liu. Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters. Journal of lipid research. 2017 02; 58(2):350-363. doi: 10.1194/jlr.m070888. [PMID: 27940481]